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Aptamers have the ability to bind tightly and selectively to the target that they are raised 
against. Medical applications of aptamers are similar to that of monoclonal antibodies. 
Aptamers can be used to detect a particular molecule for diagnostic purposes or they can be 
used to disrupt a specific molecular interaction for therapeutic purposes. Compared to 
antibodies, aptamers are smaller, more stable, cheaper to produce, and easy to modify by 
chemical means. We have developed a series of aptamers that target gluten, the storage 
protein found in wheat, barley, and rye. Gluten is the environmental factor responsible for 
celiac disease, an autoimmune-like disorder that damages the intestinal lining in genetically 
susceptible individuals. We conducted a gluten challenge test using celiac disease patient-
derived T cells where our best aptamer resulted in a 32% reduction in T cell activation. In this 
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1.1 Immunity and autoimmune disorders 
Immunity (from the Latin word immunis meaning “exempt”) is defined as inherited, 
acquired, or induced resistance to infection by a specific pathogen (1). The immune system is 
composed of two major subdivisions, (i) the innate, non-specific immune system and (ii) the 
adaptive, specific immune system (Figure 1.1). The innate immune system is the first line of 
defense against foreign pathogens while the adaptive immune system acts as a second line of 
defense and also provides protection against future re-exposure to the same pathogen.  
The immune system has the ability to distinguish non-self from self particles. When 
this ability is compromised, our immune system mistakenly attacks and damages healthy 
body tissues, resulting in autoimmune disorders. There are more than 80 different types of 
autoimmune disorders. Individuals susceptible to autoimmune disorders are genetically 
predisposed to the autoimmune response triggered by exposure to specific antigens. This 
genetic susceptibility is linked to the presence of a specific major histocompatibility complex 
(MHC) allele, located on chromosome 6 of the human genome (Figure 1.2). These alleles 
code for MHC class II molecules which are membrane-anchored proteins found on 
specialized antigen presenting cells (APCs) like macrophages, dendritic cells and B cells. 
These proteins present exogenous antigens to helper T cells (TH). For example, multiple 
sclerosis is primarily associated with the MHC class II gene HLA-DRB1, whereas insulin-
dependent diabetes mellitus (IDDM), also known as type 1 diabetes (T1D), is associated with 




Figure 1.1: Classification of immunity. Immunity can be broadly classified as innate and 
adaptive. Innate immunity is non-specific and develops in response to the appearance of a 
pathogen in the body. Adaptive response involves a more complex pathway involving the 
recognition and presentation of an antigen to the lymphocytes.  
 
Figure 1.2: A. Human leukocyte antigen (HLA) system: the major histocompatibility 
complex in humans. (Source: http://psychology.wikia.com/wiki/Human_leucocyte_antigen). 




1.2 Celiac disease 
Celiac disease (CD), also known as gluten-sensitive enteropathy or nontropical sprue, 
is a diet-induced autoimmune-like disorder caused by exposure to wheat-derived gluten and 
other prolamins (4). CD has a prevalence of about 1% in the Caucasian population. The 
gluten-induced autoimmunity is characterized by varying degrees of intestinal inflammation, 
resulting in villous atrophy, crypt hyperplasia, and infiltration of intraepithelial lymphocytes 
(IELs) in the small intestine (5) (Figure 1.3, A). Endoscopic appearance in CD include 
decreased number of folds in the small intestine (three folds per endoscopic field is normal) 
and ‘scalloping’ of the intestinal walls (Figure 1.3, B). The highly variable clinical 
presentations of CD are classified based on the presence of gastrointestinal symptoms. In 
children, the disease is commonly presented with chronic diarrhoea, abdominal distention, 
short stature and anaemia (6). In adults, a wider spectrum of symptoms is observed, although 
classical cases of the disease are usually accompanied by chronic diarrhoea, short stature and 
malabsorption (7). A subclinical, asymptomatic form of CD has also been found that presents 










Figure 1.3: A. Villi in normal intestinal lining and celiac disease affected intestine lining. (8) 
B. Endoscopic view of celiac disease progression in small intestine: (left to right) normal 
small intestine where usual ‘folds’ can be seen; celiac disease-affected small intestine with 
decreased number of folds; and celiac disease-affected small intestine with folds showing 
‘scalloping’ or notching. (Source: www.celiacdiseasecenter.org) 
 
1.3 Factors contributing to celiac disease pathogenesis 
Disease development in CD involves a complex interplay of genetic and 
environmental factors (Figure 1.4). The class II major histocompatibility complex (MHC II) 
allele, HLA-DQ2, has been associated with over 90% of diagnosed CD patients (9). Patients 
who are HLA-DQ2 negative express HLA-DQ8. A wheat protein called gluten acts as the 
primary environmental trigger of CD. Gluten-reactive CD4+ T cells of CD patients recognize 
a diverse set of gluten epitopes presented by HLA-DQ2 or DQ8 molecules. These epitopes 
are partially digested gluten, which is resistant to complete degradation by gastrointestinal 
proteases. These immunogenic peptides, rich in proline and glutamine residues, remain in the 





contributes to CD development by selectively deamidating gluten peptides in the intestine, 
increasing the peptides’ negative charge (9). tTGase is a calcium-dependent, multifunctional 
enzyme chiefly associated with post-translational modifications in proteins (10, 11). HLA-
DQ2 and -DQ8 molecules have distinctive peptide binding motifs characterized by 
preference for negatively charged amino acids at specific positions in bound peptides (12). 
Deamidated gluten peptides display up to seven-fold higher affinity for HLA-DQ2 compared 
to unmodified gluten peptides (13). The gluten peptide-HLA-DQ2/-DQ8 complex on the 
surface of antigen-presenting cells are recognized by HLA-DQ-restricted anti-gluten CD4+ T 
cells in the lamina propria which mediate the adaptive immune response associated with CD. 
The ensuing inflammatory cascade involving the release of the dominant cytokine interferon-
γ (IFN-γ) results in inflammation and damages the intestinal tissue leading to the various 





Figure 1.4: CD is a multifactorial disease involving the interplay of gluten, tTGase, HLA-DQ 
molecules and gluten-specific T cells. 
 
 
1.4 Gluten and the 33-mer peptide 
Gluten is classified into two major solubility fractions, gliadins and glutenins (Figure 
1.5), which are known to contain multiple peptides with T cell stimulatory capacity (15). The 
primary toxic components in wheat gluten are the proline- and glutamine-rich gliadins. These 
gliadins undergo incomplete gastro-intestinal digestion to give rise to relatively large peptide 
fragments. One 33-residue peptide, LQLQPFPQPQLPYPQPQLPYPQPQLPYPQP-QPF, 
which is naturally formed by gastric and pancreatic digestion of α2-gliadin, contains six 
partially overlapping copies of three different T cell epitopes: α-I (PFPQPQLPY; one copy), 
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α-II (PQPQLPYPQ; three copies), and α-III (PYPQPQLPY; two copies) (Figure 1.6). This 
peptide, also called the celiac superantigen (16, 17) is an excellent substrate for tTGase and 
has been shown to be a highly potent T cell stimulator (18, 19). In this thesis, this 33-mer 
peptide will henceforth be referred to as Glia33Q.  
Three specific glutamine residues in Glia33Q (underlined) are converted to negatively 
charged glutamic acid residues through deamidation catalyzed by tTGase released by 
intestinal epithelial cells (Figure 1.6). The deamidated Glia33E peptide can bind to HLA-
DQ2 and -DQ8 molecules with very high affinity (18, 19). This leads to the gluten-specific T 
cell activation. 
 





Figure 1.6: The native and deamidated 33-mer peptides. Three Gln residues in Glia33Q 
(highlighted in green) undergo selective deamidation by tTGase, to form Glia33E that 
contains three newly formed Glu residues. The three epitopes, α-I, α-II and α-III, are 
highlighted. 
 
1.5 Current therapies for celiac disease 
The only known effective treatment for CD patients is strict adherence to a lifelong 
gluten free diet that is often difficult to sustain. Thus, there is an increased interest in 
developing therapeutic options that could ameliorate the burden of dietary restrictions. 
Several new therapies for celiac disease are in the development phase based on the current 
understanding of the key genetic and environmental factors contributing to its pathogenesis. 
The first therapeutic route involves the targeting of gluten proteins. These include growing 
hybrid wheat species that lack the immunogenic gluten-derived proteins (20). Although the 
hybrid varieties show significant differences in the levels of T cell stimulatory gluten 
epitopes, gene deletions involved in the hybridization process also compromise the 
viscoelasticity of the bread (21). Another gluten-based strategy involves fragmenting the 
immunogenic proline-rich gluten through oral supplementation of prolyl endopeptidases 
(PEP). In vitro studies have shown that PEP together with brush-border membrane (BBM) 
enzymes are effective in reducing the number of immunogenic peptides in gluten (22, 23). 
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However, ex vivo studies have shown that high concentrations and long durations (500 
mU/mL for 3 hours) of PEP supplemented with BBM are required for sufficient 
detoxification of gluten (24). Thus, the safety and feasibility of using such high enzyme 
concentrations over prolonged periods remain to be evaluated (25). A recent study has 
reported the ability of a polymeric resin to bind gluten proteins under simulated gastric and 
intestinal conditions (26). However both the effectiveness of such a polymer as well as clarity 
on the amount of gluten that can be detoxified in vivo by a given dose of the polymer are 
still to be established. The second therapeutic route involves targeting the ubiquitous enzyme 
tissue transglutaminase (tTGase). Given that deamidation is a critical event in the generation 
of a full-blown gluten-specific T cell response, inhibiting tTGase is another approach for 
reducing the immunostimulatory properties of the glutamine-rich gluten. However, tTGase is 
involved in several physiological processes such as cellular proliferation, differentiation and 
apoptosis. In fact, tTGase knockout mice have been found to develop complex systemic 
disorders (27). Therefore, the ideal tTGase inhibitor for CD treatment should be restricted to 
the small intestinal mucosa. Although some imidazolium-derived compounds were found to 
inhibit tTGase activity, their interaction with critical biomolecules makes them unsuitable for 
in vivo studies (28, 29). Recently, dihydroisoxazole compounds have been shown to be 
effective tTGase inhibitors. Oral administration of such compounds in animals showed 
minimal systemic effect but have a short serum half-life (30, 31). The third possible treatment 
route involves exposing the immune system to low doses of the antigen that leads to 
induction of tolerance by regulatory T cells and production of anti-inflammatory cytokines. 
An earlier study used intranasal administration of α-gliadin in a mouse model for inducing 
tolerance (32, 33). This approach, however, still lacks human studies. The fourth therapeutic 
route involves blocking gluten peptides from binding to HLA-DQ molecules. HLA-DQ2 
blockers have been developed by altering the structure of the gliadin peptide. Such blockers 
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with improved HLA-DQ2 affinity have been reported to effectively inhibit HLA-DQ2-
mediated antigen presentation (34, 35). Recently, a library of peptides with high affinity for 
HLA-DQ2 has been developed by combining the optimal residues in each position of the 
HLA binding pocket (36). Such an approach may therefore be safe but it will be a challenge 
to design an effective blocker that would completely suppress the activation of gluten-
reactive T cells.   
 
1.6 Conventional drug development 
Improved scientific techniques have identified increasing number of molecules 
involved in the pathology of different diseases, which could serve as potential targets for drug 
development (37, 38). However, there are issues that limit the drug development processes 
from keeping pace with the growing number of potential drug targets (39). One such 
limitation is the early-phase identification of potential leads.  
Conventional drug discovery methods involve screening of large synthetic libraries to 
identify initial hits that interact with high affinity and specificity with the target molecule 
(Figure 1.7). This is a critical phase in the drug development process. However, such 
conventional screening approaches lead to a target-rich, lead-poor situation (37). Another 
concern with such a conventional approach is that libraries consist of only known molecules, 




Figure 1.7: Drug discovery timeline. Lead selection can take up to 2 years. (40) 
 
1.7 Aptamers and SELEX  
Aptamers are nucleic acid ligands, ssDNA or RNA, that recognize and bind to their 
target with high affinity and specificity (Figure 1.8). The term aptamer is derived from the 
Latin word aptus which means “fitting” and the Greek word meros meaning “particle”. 
Introduced by Tuerk and Gold in 1990 (41), aptamers are selected from a large library of 
randomized sequences (~10
15
 molecules) through an in vitro technique called SELEX 
(Systematic Evolution of Ligands by EXponential enrichment) (41, 42). Target specificity of 
aptamers is attributed to their unique three-dimensional structure characterized by stems, 
loops, bulges, hairpins, etc., that result in specific non-covalent interactions such as stacking 
of aromatic rings, electrostatic and van der Waals interactions, and hydrogen bonding (43, 
44). The number of conformations an aptamer is able to adopt is approximated to be 1.8
N
, 
where N is the number of bases in the sequence (45). In addition, an extensive number of 
unique aptamer molecules (4
N
) could be generated by permutation of the different types of 
bases in a given sequence.  
Predominantly unstructured in solution, in presence of the target, aptamers undergo 
adaptive conformational changes for the formation of the binding complex (46, 47, 48, 49). 
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Target binding by aptamers result in formation of complexes where the target is an inherent 
part of the aptamer structure (43). This characteristic of aptamers has been exploited in the 
generation of ‘aptabeacons’ (50, 51, 52). To date, aptamers have been selected for a variety 
of targets, including carbohydrates (53, 54, 55), peptides (56, 57, 58), proteins (59, 60, 61) 
and whole cells (62, 63, 64). Binding affinity of an aptamer to its target is comparable to that 
of antigen-antibody complexes typically in the µM to nM range.  
In comparison to antibodies, aptamers are better binders of small molecules, because 
(i) their small size can discriminate functional groups between similar structures with greater 
accuracy (65) and (ii) in vitro selection of aptamers does not require hapten, which is needed 
for selection of antibodies against molecules having molecular weight below 5,000 Da (66). 
Aptamers can be chemically modified to improve their pharmacokinetic and 
pharmacodynamic properties, aiding in their development as potential therapeutics. Examples 
of such modifications include addition of polyethylene glycol (PEG) moieties as higher 
molecular weight vehicles to increase their bioavailability, and capping of aptamer 3’ ends to 
prevent degradation by exonucleases (67).  
SELEX is an iterative process comprised of 4 main steps (Figure 1.9):  
(i)  Binding aptamers to the target 
(ii)  Partitioning weak binding aptamers  
(iii)  Eluting strong binding aptamers  
(iv)  Amplifying strong binders for the subsequent round of SELEX 
However, there is no standardized aptamer selection protocol that can be applied for 
all targets. The SELEX experimental design and specific selection conditions have to be 
optimized in accordance with the nature of the target. At the end of SELEX, the resulting 
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aptamer pool consists mostly of high-affinity aptamers that constituted a very small fraction 
of the initial aptamer library.  
The robustness of the process, the high specificity and sensitivity of the generated 
aptamers towards their targets, and the ability to introduce post-SELEX modifications in the 
aptamers make SELEX a powerful technology in therapeutic development. The first FDA 
approved therapeutic aptamer is the anti-human VEGF (vascular endothelial grow factor) 
aptamer Pegaptanib (Figure 1.10). A pegaptanib sodium injection called Macugen1 entered 
clinical use in 2004 for the treatment of wet age-related macular degeneration (68). 
 
 
Figure 1.8: Target recognition by an aptamer. The aptamer adopts a unique three-dimensional 





Figure 1.9: The iterative steps of SELEX involving binding, washing, elution and 
amplification. 
 
Figure 1.10: Sequence and predicted secondary structure of post-SELEX modified 
Pegaptanib, the anti-VEGF RNA aptamer (68). 
 
1.8 Scope of the project and aim 
We have developed ssDNA aptamers against the native (Glia33Q) and the deamidated 
(Glia33E) 33-mer peptides with the aim of using them to inhibit the tTGase-mediated 
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deamidation and HLA-DQ2 loading events respectively. The binding affinity of our aptamers 
to Glia33Q and Glia33E has been determined using isothermal titration calorimetry. Their 
ability to inhibit deamidation of the Glia33Q peptide was investigated using a 
spectrophotometric tTGase assay and their ability to inhibit DQ2 loading of the Glia33E 







































Figure 2.1: Schematic representation of methods employed. 
 
 
2.1 Synthesis of gluten peptides  
The two peptides, Glia33Q (LQLQPFPQPQLPYPQPQPLYPQPQLPYPQPQPF) and 
Glia33E (LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF) were synthesized using 
standard 9-Fluoren-9-yl-methoxycarbonyl (Fmoc) based solid phase peptide synthesis 
(SPPS). Wang resin was used as the initial solid support for building the peptides. The SPPS 
protocol includes alternating cycles of coupling and de-protection. 
Coupling: This process includes activation of the free carboxyl group of an amino acid using 




Figure 2.2: Coupling step in SPPS. 
 
Deprotection: This process includes removal of the amine protecting Fmoc group by using 
20% v/v piperidine in DMF/DMSO (Figure 2.3). 
 
Figure 2.3: Deprotection step in SPPS. 
 
A completely synthesized peptide was cleaved off the resin using a mixture of 95% 
trifluoroacetic acid, 2.5% triisopropylsilane and 2.5% water. Peptide was extracted from the 
mixture by precipitating in ice cold ether. The resulting precipitate was dissolved in 50% 
acetonitrile/water and lyophilized. 
Peptides were purified by reverse-phase HPLC (Shimadzu) on a semi-preparative C18 
column (Phenomenex) using a water-acetonitrile gradient in 0.05% (v/v) TFA. Peptide purity 
was > 95%. Peptides were characterized using MALDI-MS (Appendix A). 
 
2.2 Peptide coupling to N-hydroxysuccinimide activated columns 
Separate affinity columns (1 mL N-hydroxysuccinimide (NHS) activated HiTrap 
Sepharose; GE Healthcare) were prepared for each peptide according to the manufacturer’s 
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instructions. The efficiency of peptide immobilization to the NHS column was determined by 
UV spectroscopy as follows:  
 Each peptide was dissolved in 1 mL of the coupling buffer (0.2 M NaHCO3, 
0.5 M NaCl, pH 8.3). 
 Peptide solutions were then injected into their respective columns with a 
syringe and incubated for 1 h at room temperature. 
 After incubation, 3 column volumes of coupling buffer were used to remove 
non-immobilized peptides and the flow through was collected. 
 1 mL of this flow-through was mixed with an equal volume of 2 M glycine-
HCl, pH 2.0 and its absorbance was measured at 280 nm.  
 Calculation:  
Loaded coupling solution, A280 × mL: 
A = A280, coupling solution × Vloaded volume of coupling solution 
Amount not coupled, A280 × mL: 
B = A280, post-coupling wash after acidification × Vvolume post-column wash × 2(dilution when 
acidified) 
Coupling yield, %: (A–B)/A × 100 
Table 2.1: Coupling yield of each gluten peptide to respective column. 





Percentage of peptide 
bound to column/ 
Coupling yield % 
 
Glia33Q 3.5 3.10 88.5% 
 




In order to deactivate any excess NHS groups and remove the non-specifically bound 
ligands, Buffer A (0.5 M ethanolamine, 0.5 M NaCl, pH 8.3) and Buffer B (0.1 M acetate, 0.5 
M NaCl, pH 4) was used to wash the columns. 
 
2.3 ssDNA library design 
A DNA oligonucleotide library containing a 25-base random sequence flanked by 
defined primer-binding sites (69) and primers were ordered (Suprenom, Singapore): 
5’GGGAGACAAGAATAAACGCTCAA-(25N)-TTCGACAGGAGGCTCACAACAGGC3’ 
(Figure 2.4); forward primer, 5’GGGAGACAAGAATAAACGCTCAA3’ and reverse 
primer, 5’GCCTGTTGTGAGCCTCCTGTCGAA3’. To enrich the presence of all DNA 
aptamer species in the original library, an ssDNA pool was generated from the original 
synthetic pool by large-scale asymmetric PCR. A 400 μL reaction mixture was prepared: 
aptamer library 4 nmol, forward primer 100 nmol, reverse primer 4 nmol (Suprenom, 
Singapore), 10X PCR buffer (New England Biolabs, country), dNTPs at 25 mM of each 
nucleotide (New England Biolabs, country), MgCl2 15 mM, Taq DNA polymerase 8 units (4 
units initially plus 4 additional units on 45th cycle to ensure enzymatic activity; Sigma 
Aldrich, country). Ninety-nine rounds of amplification were performed at 94 °C denaturing 
(1.5 min), 56 °C annealing (0.5 min) and 72 °C extension (1.5 min) in a thermocycler. A final 




Figure 2.4: Starting library design and unidirectional PCR: The library consists of a 25-base 
long random sequence flanked on either side by primer regions. The first cycle in the PCR 
results in a double stranded product as result of extension by the reverse primer. This product 
now separates into two strands in the second cycle having regions available for annealing and 
subsequent extension by reverse as well as forward primer. This continues until the reverse 
primer is used up. In the following amplification cycles, the forward primer anneals to the 3’-
5’ strand resulting in the formation of the original library sequence. 
 
2.4 In vitro selection of aptamers to immobilized gluten peptides: SELEX 
A physiological buffer was used in aptamer selection: 2.7 mM KCl, 137 mM NaCl, 5 
mM MgCl2, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.3. Prior to the selection process a 
negative selection was performed. The initial amplified aptamer pool was subjected to a 10 
min heating at 92˚C followed by fast cooling on ice for 2 min. This was mixed with selection 
buffer to make a volume of 1 mL and injected into an empty column (without any peptide 
coupled). The flow-through and the washes were retained, amplified and used for the first 
selection round. This step was carried out to remove aptamer sequences that bound to the 
column constituents.  
The amplified ssDNA aptamer pool from the negative selection was first subjected to 
a 10-minute heating at 92˚C followed by immediate cooling on ice. Selection buffer was then 
added to a volume of 1 mL. Each target peptide was incubated with the starting pool for 1.5 h 
at room temperature. Non-binding and weakly binding species were removed by washing the 
column with 7 column volumes of selection buffer. Tight binding aptamers were eluted with 
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a high salt concentration elution buffer (2.7 mM KCl, 1.5 M NaCl, 5 mM MgCl2, 10 mM 
Na2HPO4, 2 mM KH2PO4, pH 7.3). Eluted aptamers were resuspended in 100 µL H2O and 
desalted using butanol precipitation. To 100 μL of oligonucleotides, 900 μL of n-butanol was 
added. This mixture was then vortexed for approximately 1 min, followed by centrifugation 
for 20 min at 13,000 rpm at 4 ºC. The supernatant was discarded and the final pellet was then 
dried and resuspended in 200 μL of autoclaved water. Primer regions flanking the random 
sequence allowed the amplification of binding aptamers by PCR. 55 μL of the resuspended 
aptamers was transferred to a sterile PCR tube and amplified by unidirectional PCR. PCR 
mixtures contained 10 μL of 10X PCR buffer, 16 μL of 100 μM forward primer, 4 μL of 1 
μM reverse primer, 4.5 μL of 15 mM MgCl2, 0.8 μL of dNTP (containing 25 mM of each 
nucleotide), 8.9 μL of autoclaved water and 0.2 μL of Taq Polymerase. PCR amplification 
(99 cycles) was carried out using the same conditions used for the initial amplification of the 
DNA aptamer library. The amplified aptamers were subsequently returned to the matrix for 
the next partitioning step. The incubation period between aptamers and peptide was gradually 
reduced in the last rounds of selection to increase the stringency of selection. Repeated 
rounds of amplification may result in incorrect PCR products. Thus, we checked the length of 
the selected aptamers and their primer regions at regular intervals. To this end, the aptamer 
pool was cloned into appropriate vectors and sequenced at the 5th, 10th and 15th rounds. 
After 20 rounds, the aptamers were passed through an NHS activated HiTrap Sepharose 
column to which no peptide had been coupled, to remove aptamers that bind to the column or 
the resin. 
 
2.5 Cloning and sequencing of selected aptamers 
The final pool of DNA aptamers was amplified for ligation into a thymidine-overhang 
vector. PCR mixtures contained 30 μL of aptamers, 5 μL of 10X PCR buffer, 1.25 μL each of 
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40 μM forward and reverse primers, 0.5 μL of dNTPs (50 mM per nucleotide), 11.8 μL of 
autoclaved water and 0.2 μL of Taq DNA polymerase. Thirty cycles of amplification were 
carried out using conditions identical to that for unidirectional PCR. The amplified product 
was ligated into a thymidine-overhang vector between two EcoRI sites (Figure 2.5) using TA 
Cloning kit (Invitrogen, country). Ligation mixture containing 3 μL of fresh PCR product, 3 
μL of sterile water, 1 μL of 10X ligation buffer, 2 μL of pCR 2.1 vector (25 ng/μl) and 1 μL 
of T4 DNA ligase was prepared and incubated at 14 °C overnight. DH5α (Novagen, country) 
competent cells were transformed with the resulting ligation product according to the 
following protocol: 
 Vials containing the ligation reactions were centrifuged briefly and placed on ice. 
 One 50 μL vial of frozen DH5α competent cells was thawed on ice for each 
transformation. 
 2 μL of each ligation reaction was pipetted into the vial of competent cells and 
mixed by stirring gently with the pipette tip. 
 The vial was incubated on ice for 30 min.  
 The cells were given a heat shock for 30 s at 42 °C and immediately the vial was 
transferred to ice. 
 950 μL of SOC medium was added to the vial. 
 The vial was incubated at 37 °C for 1 h at 225 rpm in a shaking incubator. 
 The vial containing the transformed cells was centrifuged at 3,500 rpm for 5 min. 
The SOC medium was decanted until about 100 μL remained. The cells were 
resuspended in this volume.  
 50 μl each from the transformation vial was spread on two LB agar plates 
containing 100 µg/mL ampicillin. 
 Plates were incubated at 37 °C overnight. 
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Individual transformants (Figure 2.6) were subsequently picked and 10 mL inocula 
were grown at 37 °C for 15-16 h in the presence of 100 µg/mL ampicillin. Plasmid DNA 
from individual transformants was isolated using the plasmid mini prep kit (Qiagen, country) 
using the following procedure.  
 Inoculated clones were pelleted by centrifugation at 3,500 rpm for 15 min at 4 °C.  
 The supernatant was decanted and each pellet was resuspended with 250 μL of 
resuspension buffer, followed by mixing with 250 μL of the lysis buffer.  
 350 μL of neutralizing buffer was added. This was then subjected to 20 min of 
centrifugation at 13,000 rpm. The supernatant containing the plasmids was 
retained.  
 To precipitate the plasmids, 800 μL of isopropanol was added, followed by 
incubation at room temperature for 15 min and then centrifugation for 15 min at 
13,000 rpm at 4 °C.  
 Isopropanol was then decanted and 1 mL of 70% ethanol was added into each 
tube. The tubes were centrifuged for another 5 min at 13,000 rpm. The ethanol 
was decanted. 
 This was followed by a short spin at 13,000 rpm for 1 min, to ensure that all traces 
of ethanol had been removed. 
  The isolated plasmids were eluted in 75 μL of autoclaved water.  
Purified plasmid DNA was subjected to EcoRI restriction digestion. The digestion 
mix containing 10 μL of isolated plasmid, 7.5 μL of autoclaved water, 1.5 μL of EcoRI buffer 
and 1 μL of EcoRI enzyme was incubated for at least 3 h at 37 °C.  
Digested products were monitored on a 2% agarose gel. A mixture of 10 μL of each 
digestion product, 2 μL of 10X Blue Juice dye (Invitrogen, Singapore) and 8 μL of 
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autoclaved water was loaded into individual wells. A mixture of 6 μL of 25 bp DNA ladder 
and 14 μL of autoclaved water was also loaded. Electrophoresis was carried out for 30 min at 
100 volts. Plasmids displaying the expected band size (approximately 75 bp) (Figure 2.7) 
were sequenced (AIT Biotech Singapore).  
 
Figure 2.5: Map of the vector pCR 2.1 showing ligation region. (Source: TA Cloning® Kit 
Version V, Invitrogen). 
 








Figure 2.7: Gel photo of restriction digestion products. Lane 5 contains the 25 bp DNA 
ladder. A 75 bp band corresponds to the correct size of product. The heavy band at the top 
corresponds to the pCR 2.1 plasmid vector.  
 
 
2.6 Assessing the ability of Glia33Q aptamers to inhibit deamidation of Glia33Q: 
tTGase assay 
2.6.1 Purification of tTGase 
Plasmid pJLP4 containing the tTGase construct was a gift from Prof. Chaitan Khosla 
(Stanford University). pJLP4 was transformed into E. coli Rosetta 2 strain. A 10 mL primary 
culture was grown at 37 °C for 17 h. This primary culture was used to inoculate 1 L of LB 
medium. All bacterial culture work was carried out in the presence of 50 µg/mL kanamycin 
and 34 µg/mL chloramphenicol. After growth at 37 °C to a stage where OD600= 0.6, the 
culture was induced by the addition of IPTG (50 µM). The cells were grown at 20 ºC for 20 
h. E. coli cells expressing recombinant tTGase were centrifuged at 5,000 rpm for 15 min. The 
pellet was resuspended in buffer A (50 mM NaH2PO4 and 300 mM NaCl, pH 8.0) and lysed 


























































containing tTGase was harvested and applied to a column containing 1 mL of cobalt resin 
(equilibrated with buffer A). After 2 h of incubation at 4 ºC, the column was rinsed with 20 
mL of buffer A. tTGase was eluted with buffer A containing 150 mM imidazole. Fractions 
containing tTGase were collected and exchanged into buffer B (20 mM Tris HCl, 1 mM 
DTT, and 1 mM EDTA, pH 7.2). The protein was further purified on a HiTrap Q column 
using a 0-1 M NaCl gradient in buffer B. tTGase eluted at 300 mM NaCl and was dialyzed 
into buffer B with 150 mM NaCl. Glycerol was added to a final concentration of 10%, and 
the protein was flash-frozen in liquid nitrogen and stored as aliquots of 500 µL at -80 °C. 
2.6.2 tTGase assay 
Progress of the deamidation reaction was followed using a continuous 
spectrophotometric assay as established previously (70) where glutamate dehydrogenase 
(GDH) is used to couple the ammonium ion from the tTGase-catalyzed deamidation to α-
ketoglutarate to yield glutamate (Figure 2.8). The associated oxidation of NADH to NAD+ 
was spectrophotometrically monitored at 340 nm. The following solutions were prepared: 5X 
MOPS buffer (200 mM MOPS, 5 mM CaCl2, 1 mM Na2EDTA, 10 mM α-ketoglutarate, pH 
7.2), 0.25 units/µL stock of glutamate dehydrogenase (GDH) in MOPS, 1.25 mM stock of 
NADH in water, 1.6 mM stock of Glia33Q in selection buffer. 1 mM solutions of each 
aptamer generated against Glia33Q peptide were prepared in selection buffer. 1:0, 1:1, 1:5 
and 1:10 ratios of Glia33Q to aptamer were tested for each aptamer. The aptamers were 
heated to 92 °C for 10 min followed by fast cooling on ice for 2 min. Prior to the assay, 1.5 
µL of Glia33Q and 2.5 µL, 12.5 µL or 25 µL of each aptamer were incubated at room 
temperature for 1 hr. This solution was then combined with 10 µL of the NADH stock 
solution, 6.4 µL of the MOPS buffer solution, 3.6 µL of the GDH stock solution, 5 µL of 10X 
selection buffer and water to a final volume of 45 µL. The deamidation reaction was initiated 
by adding 5 µL tTGase (0.1 μg/µL) to the assay mixture, and NADH consumption was 
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monitored for 45 min. A non-specific Muc1S2.2 aptamer was used as control. NADH 
consumption was monitored at 340 nm for 45 min using a BioSpec-mini analyzer (Shimadzu, 
country). To check tTGase activity before each set of experiments, a blank solution was 
prepared where the enzyme solution was replaced by water.  
We wondered if using two aptamers would have an enhanced effect on the inhibition 
of NADH oxidation. To this end, we carried out tTGase assay with aptamer combinations. 
Peptide to aptamer combination ratios of 1:5:5 were used. The same protocol as that used 
with single aptamers was followed.  
 
Figure 2.8: The GDH-linked continuous spectrophotometric assay for following tTGase 
activity. Ammonium ion produced by the tTGase-mediated deamidation of a glutamine 
residue in the gluten peptide is utilized by GDH for the reductive amination of α-
ketoglutarate to L-glutamate while simultaneously oxidizing NADH to NAD
+
. 
2.7 Assessing the ability of Glia33E aptamers to inhibit HLA-DQ2 loading of Glia33E: 
peptide exchange assay 
Peptide exchange assay measures the interaction between HLA-DQ2 protein and the 
Glia33E peptide (Figure 2.9). Increasing amounts of Glia33E aptamers (1:1, 1:5 and 1:10) 
were used to assess their ability to inhibit HLA-DQ2 loading of Glia33E. The following 
concentrations of aptamers were prepared: 200 µM, 100 µM and 20 µM. The aptamers were 
heated to 92 °C for 10 min followed by fast cooling on ice for 2 min. Prior to the assay, 
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FAM-Glia33E and each aptamer were incubated at room temperature for 1 h (Table 2.2). 
Thrombin-treated DQ2 was incubated with the FAM-Glia33E-aptamer complex at 37 °C in a 
1:1 mixture of PBS buffer and McIlvaine's citrate-phosphate buffer (pH 7.3). In the control, 
thrombin-treated DQ2 was incubated with only FAM-Glia33E. For all experiments, the ratio 
of FAM-Glia33E to thrombin treated DQ2 was kept constant at 1:25 (i.e. 0.2 µM FAM- 
Glia33E and 5 µM DQ2). Peptide binding was measured by high performance gel filtration 
chromatography (HPGFC) with fluorescence detection. 10 µL of reaction mixtures were 
injected into a GE Superdex 200 size exclusion column and eluted with the PBS buffer at 0.7 
mL/min after 3 h of incubation. The DQ2-peptide complex eluted at approximately 20 min, 
with free peptides emerging approximately 5 min later. The same amount of FAM-Glia33E 
as used in the assay was injected into the column and the area under the curve was calculated. 
This was used to calculate the amount of peptide that was loaded onto DQ2. Approximately 
2% of the FAM-Glia33E was found to bind to DQ2. Assuming 1:1 interaction between DQ2 
and FAM-Glia33E, the amount of the complex formed was calculated. This amount of DQ2-
FAM-Glia33E complex formed was taken as the baseline. The amount of complex formed in 
presence of the different aptamer ratios was thus calculated as the difference between the 




Figure 2.9: Schematic outline of the peptide exchange assay. 
 
Table 2.2: Amount of FAM-Glia33E and aptamers incubated for 1:1, 1:10 and 1:100 ratio 
experiments in the peptide exchange assay. 
FAM-Glia33E (1.9 µM) Aptamer (20 µM) 
1:1 
Aptamer (100 µM) 
1:5 
Aptamer (200 µM) 
1:10 
1 µL 1 µL 1 µL 1 µL 
 
   
    
2.8 Binding affinity measurement of aptamers  
MicroCal VP-ITC (GE Healthcare) was used to investigate the interaction of the 
gluten peptides (Glia33Q and Glia33E) with their respective aptamers. An unrelated aptamer, 
Muc1S2.2, served as negative control. For all sequences, only the internal, 25 base, variable 
region of the aptamers was used. All peptide and aptamer solutions were prepared in 
selection buffer, pH 7.34 to ensure that the heat change due to buffers is minimized. All 
solutions were degassed under vacuum for 10 min at 25 °C followed by centrifugation at 
13,000 rpm for 5 min just before performing the binding studies. The sample cell was loaded 
with 2 mL of each aptamer and a 400 µL injection syringe was loaded with peptide. The ITC 
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instrument was equilibrated to 25 °C while stirring at 329 rpm. A total of 25 injections of the 
peptide were introduced into the sample cell. The program was set such that 24 × 10 µL 
injections were delivered with 300 s between each injection. The first injection was 2 µL and 
this data point was masked because material diffuses from the tip of the injection syringe 
during the equilibration period. The baseline of the isotherm was smoothened and barring the 
first peak, other peaks were integrated to obtain the heat change. The stoichiometry (N), the 
association constant (KA), enthalpy ΔH and entropy ΔS were calculated using ORIGIN™ 
software package provided by MicroCal (GE Healthcare). 
Since the two gluten peptides are highly similar in sequence, differing only in 3 
residues, if the Glia33Q aptamers bound to Glia33E and vice versa, we could narrow down 
the site of interaction to be somewhere that is shared by both the peptides. To determine 
whether the aptamers had a binding site common to both the peptides, we also carried out 
cross-studies using Glia33Q aptamers with Glia33E peptide and vice-versa. 
Table 2.3: List of the concentrations of peptides and aptamers used in the ITC experiments. 




0.52 Apt33E1.10 31.6 
0.58 Apt33E1.20 25.6 
0.48 Muc1S2.2 21.2 
 
Glia33Q 
0.49 Apt33Q1.60 36.7 
0.43 Apt33Q1.70 23.3 
0.52 Apt33Q1.80 40.3 
0.49 Muc1S2.2 21.2 
 
2.9 Secondary structure prediction of functional aptamers 
The aptamers that showed significant ability to inhibit tTGase activity and DQ2 
loading were considered functional. The minimum free energy structure (71) of the functional 
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aptamers was calculated using the Mfold program with the 137 mM Na
+
 and 5 mM Mg
++
 
folding algorithm (72). 
2.10 Truncation studies of functional aptamers  
     2.10.1 Secondary structure prediction 
Secondary structures of the functional aptamers were determined using Mfold in 137 
mM Na
+
 and 5 mM Mg
++
 folding algorithm. The minimum free energy (MFE) structure was 
determined. Truncations of the functional aptamers were made based on the original 
predicted secondary structures such that the basic hairpin motif was not lost while 
simultaneously ensuring that they had the same or lower ΔG value. 
     2.10.2 Circular Dichroism Spectroscopy  
CD spectra of the functional aptamers and their truncated species were recorded using 
a spectropolarimeter (JASCO J-810). Aliquots of 300 µL of each aptamer/truncated species 
were taken in a CD cuvette of 0.1 cm path length and placed in a thermostable holder. CD 
spectra were recorded from 220 to 350 nm between 25 °C to 100 °C at a rate of 5 °C/min. For 
Apt33Q1.60 and Apt33Q1.61, spectra were collected between 5 °C to 100 °C. All aptamer 
solutions for the CD spectroscopic study were prepared in selection buffer. 
 
     2.10.3 Isothermal Titration Calorimetry 
Affinity profiles of the truncated aptamers were characterised by isothermal titration 





2.11 T cell proliferation assay 
The ability of two functional Glia33Q aptamers and three Glia33E aptamers to inhibit 
T cell activity was investigated by the T cell proliferation assay. These experiments were 
carried out by our collaborators at the University of Oslo in Norway.  
Table 2.4: List of peptides and aptamers tested in the T cell assay. 
1. Apt33Q1.10 + Glia33Q + tTGase 2. Apt33Q1.20 + Glia33Q + tTGase 
3. Apt33E1.10 + Glia33E 4. Apt33E1.20 + Glia33E 
5. Apt33E1.30 + Glia33E 6. Muc1S2.2 + Glia33Q + tTGase 
7. Muc1S2.2 + Glia33E 8. Glia33Q + tTGase 
9. Glia33E  
 
The aptamers were tested at concentrations of 0.25 µM, 2.5 µM and 25 µM, while the 
Glia33Q and Glia33E concentrations were kept constant at 0.25 µM.  
On day 1, 100 µM solutions of the aptamers were prepared in selection buffer. The 
aptamers were heated to 92 °C for 10 min followed by fast cooling on ice for 2 min. The 
peptides and their respective aptamers were incubated for 1 h. 50 µg/mL human tTGase was 
added to the Glia33Q-aptamer mixture and incubated for 1 h at 37 °C. 25 µL of each mixture 
was transferred to a well in a round bottom 96-well plate. Triplicate experiments were 
performed. 
Cells from a DQ2 homozygous, EBV-transformed B lymphoblastoid cell line, CD114 
were used as antigen-presenting cells (APCs). Live cells were irradiated using 80 Gy of 
radiation. For fixation, the cells were resuspended in 3.9 mL RPMI medium. To this solution 
100 µL of 2% glutaraldehyde was added and incubated for 90 s at room temperature. This 
was followed by adding 0.8 mL of 1.2 M glycine and 60 s of incubation at room temperature. 
Another 45 mL of RPMI medium was added before spinning the cells. The APCs were 
resuspended in 10% human serum in RPMI medium. 75 µL containing 75,000 cells was 
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added to each well. On day 2, the plates were washed twice before the T cells were added (50 
µL of 10% human serum in RPMI medium containing 40,000 cells in each well). Two T cell 
clones TCC 430.1.142 (specific for αI/αIII epitopes) and TCC 678.3.22 (specific for αII 
epitope) were tested. On day 4, 20 µL 
3
H thymidine was added to each well. Cells from the 
plates were harvested in Tomtec cell harvester and counted in Wallac 1450 Microbeta liquid 





























3.1 Selection of unique ssDNA aptamers that bind to the gluten peptides  
Thirty clones from each final aptamer pool were sequenced after selection based on 
correct insert size as determined by gel electrophoresis. Eight unique sequences for Glia33Q 
and six unique sequences for Glia33E were identified (Table 3.1). The aptamers were named 
according to the particular target they were selected for. For example, aptamers targeting the 
Glia33Q peptide from α-gliadin were named Apt33Q1.x0, where ‘1’ stood for first generation 
and ‘x’ could be 1, 2, 3 etc (Table 3.1). Similarly, aptamers for Glia33E were named 
Apt33E1.x0.  
Table 3.1: Glia33Q and Glia33E aptamers with their sequence and length (number of bases). 




Apt33Q1.10 5'-GATGCGGATA CTGGGTCATG TGCAT-3' 25 
Apt33Q1.20 5'-CGCCGGATCT TAACCGTGTA CCCTG-3' 25 
Apt33Q1.30 5'-ATCTTGGACT TTCACCGAGG GGAGT-3' 25 
Apt33Q1.40 5'-CCTACGTCCA GGCTAGAGAA AGTAA-3' 25 
Apt33Q1.50 5'-GAGCGAGGCC AATACTTACC AGATG-3' 25 
Apt33Q1.60 5'-GGCTCTACAG GTGGGGTATG AAATT-3' 25 
Apt33Q1.70 5'-GGGTGGATAT ATGGGGATAT CAGCC-3' 25 




Apt33E1.10 5'-TGCGCACGTG CAGCAGTACG-3' 20 
Apt33E1.20 5'-TGCGCACGGG GCGGGGGACG G-3' 21 
Apt33E1.30 5'-CACGGCACGG CGCCATGCAC GTCA-3' 24 
Apt33E1.40 5'-CACGGCACGG CGCAACGTAC GGTGG-3'  25 
Apt33E1.50 5'-CGCGACGTGA CGTACTGCTG CGTCA-3' 25 










3.2 tTGase assay to assess ability of Glia33Q aptamers in inhibiting tTGase-mediated 
deamidation 
3.2.1 Purification of tTGase                                           
 
Figure 3.1: Anion-exchange chromatography profile of tTGase. Protein elution fractions from 
the affinity chromatography column were applied to the HiTrap Q column and eluted by a 
linear NaCl gradient from 0 to 1.0 M. tTGase (79.5 kDa) was eluted at 300 mM NaCl. 
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Figure 3.2: SDS-PAGE of tTGase purified by affinity chromatography and anion-exchange 
chromatography. The molecular weight of tTGase is 79.5 kDa. The lanes from left to right 
(Lane1 to Lane 9) are: Flow-through fraction of the cobalt chelated affinity chromatography, 
first washed fraction, second washed fraction, last washed fraction, first elution fraction, 
second elution fraction, last elution fraction, purified tTGase fraction from anion exchange 
chromatography and molecular weight marker. 
  
 
Figure 3.3: SDS-PAGE showing the different fractions of purified tTGase from anion-
exchange chromatography. Lane 1 was loaded with molecular weight marker, lane 2 was left 
empty, lane 3 was loaded with sample from affinity chromatography and lanes 4 to 13 
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3.2.2 Inhibition of Glia33Q deamidation by Glia33Q aptamers  
Progress of the deamidation reaction was followed using a continuous 
spectrophotometric assay where glutamate dehydrogenase (GDH) is used to couple the 
ammonium ion from the tTGase catalyzed deamidation to α-ketoglutarate to yield glutamate. 
Prior to the assay, Glia33Q and each aptamer were incubated at room temperature for one 
hour. This solution was then added to a solution containing NADH, GDH and Mops. The 
deamidation reaction was initiated by adding tTGase to the assay mixture, and NADH 
consumption was monitored for 45 min. 
tTGase assay - Single aptamer studies 
The tTGase catalyzed deamidation reaction was monitored in the presence (at 1:1, 




Figure 3.4: Inhibition of the tTGase catalyzed deamidation reaction by the Apt33Q aptamers. 
(A) Apt33Q1.60, (B) Apt33Q1.70, (C) Apt33Q1.80 and (D) Muc1S2.2. 
 
In the absence of aptamer (inverted triangle black Fig.3.4), approximately 80% of 
NADH is consumed within 45 minutes. Therefore, 80% NADH utilization represents 
deamidation of all glutamine residues present in the initial reaction mixture. Addition of 
Muc1S2.2 aptamer to the reaction mixture (at 1:1 or 1:5 or 1:10 peptide:aptamer ratio) had no 
effect on the tTGase catalyzed deamidation reaction, which is expected because this aptamer 
does not bind to the Glia33Q peptide. Of the three Apt33Q aptamers tested, Apt33Q1.80 
exhibited the highest inhibitory activity. When used at 1:10 peptide:apatamer ratio, 
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Apt33Q1.80 displayed 60% inhibition. At 1:5 and 1:1 peptide:aptamer ratio, Apt33Q1.80 
showed 28% and 6% inhibition, respectively. 
 tTGase assay - Combination studies with Apt33Q1.60, Apt33Q1.70 and 
Apt33Q1.80:  
Combination studies with Apt33Q1.60, Apt33Q1.70 and Apt33Q1.80 were carried 
out and monitored using the tTGase assay. The ratio of peptide to each of the pair of aptamers 
was 1:5:5. 
 
Figure 3.5: Inhibition of the tTGase catalyzed deamidation reaction by the Apt33Q aptamer 
combinations. (A) Apt33Q1.60 & Apt33Q1.70, (B) Apt33Q1.70 & Apt33Q1.80 and (C) 
Apt33Q1.60 & Apt33Q1.80. 
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Table 3.2: Percentage of NADH consumed after 45 mins in single aptamer experiments 
(peptide:aptamer = 1:5) and combination experiments (peptide:aptamer1:aptamer2 = 1:5:5). 
 
Using two aptamers simultaneously did not result in significantly improved inhibition 
(Table 3.2). This is expected if the three aptamers have overlapping sites of interaction on the 
Glia33Q peptide, and therefore compete for the same site. In fact, the only combination that 
seems to have any effect is the Apt33Q1.70+Apt33Q1.80 combination. This combination 
results in greater % NADH consumption (56%) than that observed when only Apt33Q1.70 
(47%) is used, but similar to that with only Apt33Q1.80 (58% NADH). Apt33Q1.80 probably 
interacts with a Gln residue that is not a part of the site of interaction shared by both the 
























54 47 58 64 56 62 
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3.3 Inhibition of DQ2 loading of the Glia33E peptide by Glia33E aptamers: peptide 
exchange assay 
 
Figure 3.6: (A) Gel filtration profile of FAM-Glia33E. (B) Gel filtration profile of standard 
peptide exchange assay. Approximately 2% of the total FAM-Glia33E gets loaded onto DQ2. 
The DQ2-FAM-Glia33E complex elutes at ~20min and the free peptide elutes 5 mins later. 
(C) Gel filtration profile of peptide exchange assay with Muc1S2.2 using peptide to aptamer 







                  
Figure 3.7: Gel filtration profile of peptide exchange assay with Apt33E1.10 using peptide to 


















Figure 3.8: Gel filtration profile of peptide exchange assay with Apt33E1.20 using peptide to 





The ability of two of the Glia33E aptamers to inhibit DQ2 loading of Glia33E was 
tested with the peptide exchange assay. 1:1, 1:5 and 1:10 ratios of Glia33E to aptamer were 







Table 3.3: Area under the curve for DQ2-Glia33E complex formed in presence of different 
ratios of aptamers. 




Mean Standard Deviation 
No aptamer - 1853529.0 216094.1 
 
Apt33E1.10 
1:1   459689.0   13250.6 
1:5   342644.7     4301.4 
  1:10   178381.3     7400.8 
 
Apt33E1.20 
1:1 1204877.0   73211.4 
1:5   215401.3   11977.6 
  1:10   120944.0     8245.5 





Figure 3.9: Peptide exchange assay with 1:1, 1:5 and 1:10 ratios of Glia33E to aptamers 
Glia33E 1.1 and Apt33E1.20. Fluorescent signals corresponding to peptide-DQ2 complex 
was taken as the maximum amount of complex formed and relative amounts of complex 
formed in presence of different ratios of the Glia33E aptamers were thus calculated. 
 
In the peptide exchange assay without an aptamer, the area under the peak 
corresponding to the DQ2-FAM-Glia33E complex was integrated. This was considered to be 


















































presence of different aptamer concentrations were calculated as fractions. Both the aptamers 
Apt33E1.10 and Apt33E1.20 displayed 90% and 93% inhibition to complex formation 
respectively, at 1:10 peptide:aptamer ratio. Using 1:10 ratio of Muc1S2.2, hardly any 
inhibition was observed (3.6%), which is expected because this aptamer does not bind to the 
Glia33E peptide. 
In the aptamer-free peptide exchange assay, approximately 2% of the Glia33E peptide 
gets loaded on to DQ2. It was interesting to note that the area under the peak for the free 
peptide decreased with increasing amounts of aptamer. This could be an indication that the 
aptamers were binding to the peptide and this interaction resulted in the quenching of FAM. 
That this was not a result of non-specific interaction is corroborated by the fact that a similar 
scenario was not observed when 10-fold excess of the Muc1S2.2 aptamer was used. 
Although the aptamers show significant inhibition to DQ2 loading, complete 
inhibition is not observed. As mentioned earlier, the Glia33E peptide contains six copies of 
three partially overlapping DQ2 restricted epitopes. That is, the Glia33E peptide can bind to 
DQ2 through any of the six binding motifs. Interaction of the Glia33E peptide with the 
Glia33E aptamers might not involve all the three epitopes at once, and Glia33E might still 
bind to DQ2. Hence, 100% inhibition of the complex formation is not observed. This can also 
be explained based on the aptamer selection technique we used. In aqueous solution, the 
secondary structure of peptides is generally random (73, 74). The aptamer selection process 
requires the peptide to be immobilized on a solid support, which to some degree, might 
restrict its flexibility. The peptide exchange assay is carried out in free solution where the 
peptide can adopt a more flexible conformation being allowed additional degrees of freedom, 
which may be unfavourable for its interaction with the aptamers that were originally selected 




While the peptide exchange assay gives a quantitative indication of the 
fraction/amount of inhibited complex in presence of the aptamers compared to standard 
conditions, it does not provide any insights into the nature of interaction between Glia33E 
and the aptamers. As mentioned before, the presence of three different epitopes complicates 
the situation even further and makes it difficult to get a conclusive readout from the 
observations. 
However, there was no doubt that the Glia33E aptamers were functionally viable and 
able to inhibit DQ2 restricted loading of Glia33E. Therefore, we proceeded to do ITC studies, 



































Figure 3.10: ITC profiles of (A) Glia33Q peptide binding to Apt33Q aptamers, (B) Glia33Q 
peptide binding to the Apt33E aptamers, (C) Glia33E peptide binding to Apt33E aptamers, 
(D) Glia33E peptide binding to Apt33Q aptamers and (E) Glia33Q and Glia33E peptide 
titrations with the non-related aptamer Muc1S2.2. All three Apt33Q and the two Apt33E 












Table 3.4: Parameters derived from the calorimetric titration of Glia33Q peptide into Apt33Q 
aptamers, Glia33E peptide into Apt33E aptamers, Glia33Q peptide into Apt33E aptamers and 
Glia33E peptide into Apt33Q aptamers. (Data from duplicate measurements are separately 
provided). 
Peptide Aptamer KA (M
-1














Apt33Q1.60 2.02E+05 0.98 0.31 7.62 -7.31 4.95 
2.94E+05 1.23 0.29 7.95 -7.66 3.40 
Apt33Q1.70 3.14E+05 2.47 0.27 7.98 -7.71 3.18 
2.37E+05 2.04 0.28 7.68 -7.40 4.21 
Apt33Q1.80 1.51E+05 1.04 0.20 7.50 -7.30 6.62 
3.36E+05 1.16 0.32 7.95 -7.62 2.97 
Apt33E1.10 8.65E+04 1.84 0.54 7.65 -7.11 11.56 
8.28E+04 1.90 0.47 7.56 -7.09 12.07 
Apt33E1.20 1.19E+05 1.89 0.93 8.28 -7.35 8.40 
1.04E+05 1.96 0.83 8.04 -7.72 9.61 







Apt33Q1.60 1.77E+05 1.50 0.64 8.04 -7.40 5.64 
1.14E+05 1.45 0.50 7.68 -7.18 8.77 
Apt33Q1.70 1.60E+05 1.97 0.45 7.74 -7.29 6.25 
1.90E+05 1.71 0.48 7.92 -7.44 5.26 
Apt33Q1.80 1.06E+05 1.39 0.58 7.56 -6.97 9.43 
1.36E+05 1.49 0.65 7.80 -7.15 7.35 
Apt33E1.10 1.61E+05 1.06 0.43 7.80 -7.36 6.21 
1.05E+05 1.12 0.66 7.53 -6.87 9.52 
Apt33E1.20 1.36E+05 1.60 0.52 7.77 -7.25 7.35 
1.32E+05 1.61 0.54 7.65 -7.11 7.57 
 
Thermodynamic characterization of the binding of the aptamers to the gluten derived 
peptides were evaluated in pH 7.4 selection buffer at 25°C using ITC. As shown in the upper 
panels of Fig. 3.10, the titrations of Glia33Q and Glia33E against the functional aptamers 
show specific binding and entropically-driven formation of complexes with endothermic heat 
of binding. As the concentration of ligand increases in the cell the availability of free aptamer 
binding sites decreases and hence lowers the amount of endothermic heat until saturation is 
achieved. The binding isotherms, which represent the incremental heat absorbed because of 
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complex formation, are shown in the lower panels. All reactions were spontaneous as 
indicated by the negative ΔG values. 
Positive ΔH is generally associated with breaking of bonds, an event that requires 
energy to be supplied to the system. The isotherms for most aptamers show a positive ΔH 
value. This is indicative of the fact that more bonds are broken than are formed during the 
binding event. This phenomenon has been reported before (75). In one paper, the authors 
examined the melting of a DNA duplex in the event of binding to a tetrapeptide. The stability 
of a DNA duplex depends on hydrogen bonds and base-stacking interactions between 
adjacent bases and the positive values of ΔH and ΔS accompanying its melting are dependent 
on both interactions (76). The authors report that in duplex DNA bound to the tetrapeptide the 
strand melting is characterized by positive ΔH (444.6 kJ/mol base pair) and this is lower than 
that observed in free DNA duplex. This indicates that separation of DNA strands at normal 
temperatures is not denaturing and since duplex restoration has also been reported after 
separation due to the presence of the tetrapeptide. Another group studying lipid-DNA 
interactions has reported positive ΔH for binding (77). They attribute this ΔH (960 cal/mol) 
to DNA-DNA repulsion in cationic lipid-DNA complex formation. In both cases, the 
interactions have been studied in detail. For both the DNA-tetrapeptide and the DNA-lipid, 
the mode of interaction and the functional groups involved and changes in conformation upon 
binding are known. In our case, although we have no information about the sites(s) of 
interaction or the structural changes involved with the binding, we speculate that the positive 
ΔH is the result of a similar phenomenon. Aptamers are known to undergo conformational 
changes in presence of their target in order to bind to them (46, 47, 48, 49). We speculate that 
the gluten aptamers exist in a stable higher order structure, with lower entropy. With the 
introduction of the target peptide, they may undergo extensive structural change involving 
breaking of non-covalent interactions, while at the same time new interactions are established 
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between the aptamer and the peptide. In such entropically-driven reactions the magnitude of 
TΔS is significantly higher than ΔH.  
The best fit to the binding curves for the titration of the gluten peptides into their 
respective aptamers was obtained by applying the one set of sites model. This model works 
for any number of sites ‘n’ if all sites have the same K and ΔH. Except Apt33Q1.70 and 
Apt33E1.20, all aptamers exhibited an n value of 1. For Apt33Q1.80, a variation was 
observed in the affinities deduced from the two separate titrations. This is probably because 
we did not attempt to integrate the baseline and reported the fitting obtained from the raw 
data. Perhaps integrating the baseline of the isotherms would help in obtaining a more 
consistent affinity. For all interactions, the calculated ΔG value was negative, implying the 
reactions were spontaneous (Table 3.4).  
Although ITC study provided a knowledge of the binding affinities between the two 
gluten derived peptides and their respective aptamers, it was difficult to derive a pattern for 
the mode of interaction. One way to derive detailed structural information from ITC 
measurements was to test the binders of Glia33Q against Glia33E and vice versa. Since the 
two peptides are highly similar in sequence and differ only in three residues, if the Apt33Q 
aptamers bound to Glia33E and vice versa, we could narrow down the site of interaction to be 
that which is shared by both peptides. Thus, cross studies were performed between Glia33E 
and the Apt33Q aptamers and vice versa, to check if the aptamers shared any similarity in the 
sites of interaction on their respective target peptides. 
The results from the cross study was quite interesting. All Apt33Q aptamers bound to 
Glia33E and all Apt33E aptamers bound to Glia33Q, exhibiting endothermic heats of 
binding. This was not surprising since Glia33Q 
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF) and Glia33E 
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(LQLQPFPQPELPYPQPELPYPQPELPYPQPQPF) share a high similarity of sequence. In 
most cases, the binding affinities were only slightly weaker than that observed with the actual 
targets. Interestingly, the titration of Glia33Q into Apt33E1.10, exhibited an n-value of ~2 
and an affinity that was 1.5 times lower compared to that with Glia33E. This indicated that 
another Glia33Q molecule was binding to a second binding site on the aptamer with similar 
thermodynamic parameters as the first. However, the interaction was not as strong as with the 
original target peptide Glia33E. The thermodynamic feasibility of complexation was apparent 
from the negative values of the free energies (ΔG) associated with complex formation. 
It should be noted that the ITC data reported here were subjected to the ‘simple math’ 
module. We feel that subtracting the actual buffer dilution profile might have resulted in 
better fitting of the isotherms. 
 
3.5 Secondary structure prediction of functional aptamers 
The minimum free energy structure of the functional aptamers was calculated using 
the Mfold program with the 137 mM Na
+
 and 5 mM Mg
++
 folding algorithm. The predicted 
structure with the smallest change in the Gibbs free energy (ΔG) was considered to be the 
most stable structure of the aptamer. The software predicted the formation of a stem-loop in 




Figure 3.11: Predicted secondary structures of the (A) Apt33Q aptamers and (B) Apt33E 
aptamers by the Mfold program. 
 
 
3.6 Truncation studies of functional aptamers  
    3.6.1 Secondary structure prediction 
Truncations of the functional aptamers were made based on the predicted secondary 
structures such that the basic hairpin motif was not lost while simultaneously ensuring that 
they had the same or lower ΔG value.  
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The truncated species of Apt33Q1.60, named Apt33Q1.61, resulted from the deletion 
of unpaired bases from the 5’ and 3’ ends (Figure 3.12 A). For Apt33Q1.70, ‘G’ was 






 positions. This removed the lone unpaired ‘G’ at the 5’ 
end, and lowered the ΔG value significantly (Figure 3.12 B). For Apt33Q1.80, the first 7 
bases from the 5’ end and the lone unpaired 3’ ‘G’ were removed. This did not change the 
ΔG value and at the same time retained the original stem-loop structure in Apt33Q1.81 
(Figure 3.12 C). For Apt33E1.10, the truncated species Apt33E1.11, had the first 5 bases 
deleted from the 5’ end and a ‘C’ added to the 3’ end. Presence of a terminal ‘C’ at 3’ end 
was found to stabilize the sequence to a great degree. In addition, the ‘T’ at position 17 was 
replaced with a ‘C’ to introduce a G-C pair in the stem region (Figure 3.13 A). For 
Apt33E1.20, major deletions were made to remove the chain of unpaired bases at the 3’ end 
and the ‘T’ at the 5’end. These however, did not change the ΔG value of the resulting 







Figure 3.12: Predicted Secondary Structures of the functional aptamers for Apt33Q and their 
truncations. (A) Apt33Q1.60 and Apt33Q1.61, (B) Apt33Q1.70 and Apt33Q1.71, (C) 
Apt33Q1.80 and Apt33Q1.81. 
 
 
Figure 3.13: Predicted Secondary Structures of the functional aptamers for Apt33E and their 





 3.6.2 Circular Dichroism Spectroscopy  
CD spectra of the functional aptamers and their truncated species were recorded using 
a spectropolarimeter (JASCO J-810). Aliquots of 300 µL of each aptamer/truncated species 
were taken in a CD cuvette of 0.1 cm path length and placed in a thermostable holder. CD 
spectra were recorded from 220 to 350 nm between 25°C to 100°C at a rate of 5°C/min. For 
Apt33Q1.60 and Apt33Q1.61, spectra were collected between 5°C to 100°C. All aptamer 
solutions for the CD spectroscopic study were prepared in selection buffer. 
 
 





Figure 3.15: CD spectra of the Apt33E functional aptamers and their truncations. 
 
The spectropolarimeter gives the raw output in ellipticity (θ), measured in 
millidegrees (mdeg). To compare the circular dichroism spectra of different samples, or the 
same sample at different concentrations, or when using the data to estimate secondary 
structure content, it is usual to normalize the machine units of millidegrees ellipticity by 





). Thus, all data obtained in millidegrees (θ) were converted to molar 
ellipticity by using the equation: [θ] = (mo*M)/(10*L*C), where mo is ellipticity in 
millidegrees, M is molecular weight (g mol
-1








                     
 





Tm = 33.4 C Tm = 13.3 C
Tm = 50.9 C Tm = 59.2 C
Tm = 71.7 C Tm = 81.9 C
Apt33E1.20 Apt33E1.21
Apt33E1.10 Apt33E1.11
Tm = 83.8 CTm = 66.9 C
Tm = 71.7 CTm = 83.5 C
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Truncated species of Apt33E1.10, Apt33Q1.70 and Apt33Q1.80 showed higher 
melting temperatures compared to the original sequences. The other truncated aptamers had 
Tm values lower than that observed for the respective original sequences. 
Apt33E1.11 (-6.03 kcal/mol) and Apt33Q1.71 (-4.10 kcal/mol) had predicted ΔG 
values smaller than Apt33E1.10 (-2.33 kcal/mol) and Apt33Q1.70 (-1.04 kcal/mol) 
respectively, which is reflected in their lower Tm values. However, completely different 
results were observed in Apt33E1.21, Apt33Q1.61 and Apt33Q1.81 even though they had the 
same predicted ΔG values as their original sequences. In fact, for Apt22Q1.61, the Tm was 
significantly low (13.3°C) compared to AptQ1.60 (33.4°C). Figure 3.17 shows that the 
predicted ΔG values exhibit a roughly linear relationship with the experimentally determined 
Tm values.  
 
































Figure 3.18: ITC profiles of (A) Glia33Q and (B) Glia33E with their respective truncated 











Table 3.5: Thermodynamic parameters derived from the calorimetric titration of Glia33E 
peptide into truncated Apt33E aptamers and Glia33Q peptide into truncated Apt33Q aptamers 













1.60E+05 1.34 0.32 7.18 -6.86   6.25 
7.05E+05 0.90 0.16 6.94 -6.77   1.41 
Apt33Q1.71 
2.42E+05 2.09 0.23 7.65 -7.42   4.13 
3.29E+05 1.70 0.20 7.56 -7.36   3.03 
Apt33Q1.81 
1.42E+05 1.38 0.52 7.74 -7.22   7.04 
1.81E+05 1.40 0.40 7.74 -7.34   5.52 
Apt33E1.11 
7.24E+04 1.03 0.90 7.86 -6.96 13.81 
6.76E+04 1.14 0.80 7.71 -6.91 14.79 
Apt33E1.21 
6.70E+04 0.91 0.87 7.86 -6.98 14.92 
7.50E+04 1.02 0.80 7.83 -7.03 13.33 
 
Apt33Q1.71 showed an affinity for Glia33Q similar to that of its original sequence 
Apt33Q1.70. This aptamer resulted from the removal of three ‘G’ bases from the original 
sequence that are probably not involved in the binding process and hence, their removal did 
not affect the affinity. For Apt33Q1.61, it was difficult to obtain conclusive information 
given the variation in the affinities. As mentioned before, this is probably because we did not 
attempt to integrate the baseline and reported the fitting obtained from the raw data. Perhaps 
integrating the baseline of the isotherms obtained from the first titration would help in 
obtaining an affinity value that was more consistent with the second. However, assuming the 
affinity value obtained from the second experiment (with a lower chi
2
 value) to be accurate, 
Apt33Q1.61 has a higher affinity than the original aptamer. This observation indicates the 
role that the deleted bases might have in the binding process. We speculate that the deleted 
bases might have played an inhibitory role in the interaction of the peptide with the binding 
site on the aptamer, and so their removal increases the affinity. Similarly, for Apt33Q1.81, 
comparing with the results obtained from the first titration of Glia33Q into Apt33Q1.80, the 
affinity remains unchanged. Surprisingly, both Apt33E1.11 and Apt33E1.21 showed a 2 
times decrease in their affinity for Glia33E. In addition, Apt33E1.21 displayed a 
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stoichiometry of 1 where as the original Apt33E1.20 exhibited n-value 1.6. Both these 
truncated aptamers resulted from the deletion of several bases and the incorporation of an 
additional ‘C’ (in the case of Apt33E1.11, to introduce a G-C pair) to increase stability. In 
fact the predicted ΔG value of Apt33E1.21 is same as that of AptE331.20. However, the 
deleted nucleotides may have been an integral part of the interaction site with the peptide, as 
is reflected by the decreased affinities, especially in the case of Apt33E1.21, where the 
stoichiometry changes. The results from the ITC studies with the truncated aptamers indicate 
that choosing truncations cannot be based on the predicted ΔG values alone. All possible 
permutations need to be tried to narrow down on the final ‘truncated lead’. This is perhaps 
why ‘lead optimization’ takes around 4-5 years and is the most important step in the 
development of an aptamer therapeutic.  
 
3.7 T cell proliferation assay  
T cell assay tests the inhibitory effect of the gluten aptamers on patient-derived T cell 
clones (TCC). Of the two TCCs tested, one was specific for the α-II epitope while the other 
for both α-I and α-III epitopes. At 1:100 peptide:aptamer ratio, Apt33E1.10 showed 30% 
inhibition to the activation of α-II specific TCC. Using the same TCC, Apt33E1.20 showed 
32% and 43% inhibition at 1:1 and 1:10 ratios respectively (Figure 3.17). Using the α-I/α-III 
specific TCC did not yield any significant results (Appendix D). 
Of the Glia33Q aptamers, Apt33Q1.10 and Apt33Q1.20 showed 24% and 22% 
inhibition respectively to α-I/α-III specific TCC at 1:1 ratio (Figure 3.18) but not to the α-II 






Figure 3.19: T cell activation in presence of Apt33E1.10, Apt33E1.20, Apt33E1.30 and 
control aptamer Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33E) to aptamers 
were used. Fixed antigen presenting cells and T cell clone 678.3.22, specific for α-II were 




Figure 3.20: T cell activation in presence of Apt33Q1.10, Apt33Q1.20 and control aptamer 
Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33Q) to aptamers were used. Fixed 
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With encouraging data from the functional assays, we further wished to study the 
effect of the aptamers on the 33-mer-HLA-DQ2 interaction in a more biologically relevant 
system. Therefore, the T cell proliferation assay was carried out by our collaborators using T 
lymphocytes derived from CD patients.  
Apt33E1.10 and Apt33E1.30 showed 30% and 31% inhibition to T cell proliferation 
respectively, using DQ2-restricted, α-II specific T cell clone TCC 678.3.22 with fixed APCs 
at 100-fold excess in comparison to the antigen Glia33E. This is in accordance with the 
stoichiometry observed for the two aptamers (Table 3.2). 
Using the DQ2-restricted, α-II specific T cell clone TCC 678.3.22 with fixed APCs, 
Apt33E1.20 showed 32% and 43% inhibition at 1:1 and 1:10 ratios respectively, which is of 
great interest as it demonstrates the inhibitory capacity of the aptamer at low amounts. This is 
not surprising given that this aptamer has a 1:1 binding stoichiometry. The reason why an 
increase in T cell proliferation is observed at 100-fold amounts of the aptamer could be that at 
such high concentrations the aptamer form aggregates and no longer bind to the Glia33E 
peptide. This is in contrast with the data obtained with 100-folds of the same aptamer in the 
peptide exchange assay. An explanation for this discrepancy is probably the difference in 
experimental time. The peptide exchange assay was completed in 3 hours whereas the T cell 
assay is carried out over five days. Such a long duration together with high concentration 
might lead to aptamer aggregation.  
We had sent out two Glia33Q aptamers, Apt33Q1.10 and Apt33Q1.20 to be tested by 
the T cell assay. It should be noted that these aptamers were sent before the ITC studies were 
carried out. We feel that the 24% and 22% inhibition shown by 100-fold excess amounts of 
Apt33Q1.10 and Apt33Q1.20 respectively, to fixed α-II specific TCC is a result of steric 
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hindrance as observed in the tTGase assay. The same explanation can be given for the 26% 
inhibition shown by Apt33Q1.10 to fixed α-I/α-III specific TCC at 1:1 ratio.  
Using DQ2-α-I/III-specific T cell clone TCC 430.1.142 none of the aptamers showed 
significant inhibition to T cell proliferation. From this data we concluded that the site of 
aptamer interaction on the Glia33E peptide involves the α-II epitope region. 
The aptamers did not show significant inhibitory capacity when irradiated APCs were 
used. Irradiated APCs are live cells, capable of processing antigens. This made us consider 
the possibility that the aptamers were dissociating from the antigens before internalization by 
the APCs. During the tTGase assay and the peptide exchange assay there is always a 
sufficient amount of aptamers in the reaction solution to interact with the antigenic peptides. 
During the T cell proliferation assay the APCs are allowed to interact with the antigens for 
more than 72 hours. In such a situation, if the aptamers dissociate from the peptides, even a 






























Aptamers are highly specific nucleic acid ligands, obtained from random sequence 
RNA or ssDNA pool against a particular target, by an in vitro selection technique called 
SELEX. Both DNA and RNA have unique characteristics that contribute towards their target 
binding abilities. DNA is more stable because of the 2’H in the deoxyribose sugar makes it 
less reactive. On the other hand RNA has 2’OH in the ribose sugar making it more easily 
hydrolysable. DNA has greater conformational flexibility because it lacks the steric hindrance 
caused by this hydroxyl group in RNA. However, this also gives RNA an extra hydrogen-
bonding site for specific interactions (78). In the past two decades both RNA and ssDNA 
aptamers have been reported against a myriad of targets. 
The critical role of the 33-mer peptide in CD pathogenesis makes it an attractive 
target for therapeutic intervention. Our study involves targeting the highly immunogenic 33-
mer peptide with ssDNA aptamers. We chose two critical and sequential molecular events as 
intervention points for the ssDNA aptamers during CD development: the tTGase-mediated 
deamidation of the native peptide and DQ2 loading of the deamidated peptide. 
It is clear that our aptamers are able to inhibit the targeted events involving the 
antigenic peptides Glia33Q and Glia33E in vitro. Although the ability of the three Glia33Q 
aptamers – Apt33Q1.60, Apt33Q1.70 and Apt33Q1.80 – to inhibit T cell proliferation needs 
to be tested, it is clear that the Glia33E aptamers are inhibitory. Apt33E1.20 seems to be the 
best aptamer showing 32% inhibition at just 1:1 peptide to aptamer ratio. This is the first time 
that an aptamer-based approach has been undertaken for the pharmaceutical intervention of 
CD or any autoimmune disorder. Our results have direct implications in the development of 
an aptamer-based therapy for CD. 
The development process of a potential aptamer to a therapeutic agent comprises of 
the following steps: 
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1. Identification of lead aptamer sequence(s).  
2. Optimization of the sequence(s), such as truncation to obtain shorter but 
functional molecule(s).   
3. Chemical modifications to make aptamers easier to synthesize on solid support 
and to optimize their pharmacokinetic and pharmacodynamic profiles. 
We are currently at step 2 in the process of developing a therapeutic agent. An 
example of a truncated aptamer is the thrombin binding aptamer (TBA), a 15-base long 
sequence obtained from a 60-base random library (79). We used a ‘rational truncation’ 
method that utilized the predicted secondary structures of the aptamer and systematically 
truncating regions without disturbing the basic stem-loop motif (80, 81). This was followed 
by binding experiments using ITC to test whether the truncated aptamers were still able to 
bind to the target peptides. The next step is to carry out functional assays to test the truncated 
aptamer.  
Typically, RNA and DNA molecules are susceptible to nuclease-mediated 
degradation which is a disadvantage for most therapeutic applications. To address this issue, 
different chemical modifications of the aptamer structure have been described that enhance 
their chemical diversity and make them suitable for various biological applications. These 
modifications are introduced at 5’- or 3’-terminus, nucleobase, sugar, and phosphate 
backbone. The addition of amino (-NH2) or fluoro (-F) pyrimidines have been found to 
enhance nuclease resistance (82, 83, 84). Another modification involves the 4’-oxygen atom 
in the nucleotide ribose ring. Addition of 4’-thio pyrimidines has been found to reduce 
nuclease-mediated degradation and increase base-pair strengths (85). The replacement of the 
DNA phosphate backbone by a phosphorothioate has also shown enhanced nuclease 
resistance (86). Apart from improving the aptamer stability, these modifications also improve 
the affinity of the aptamer in the cellular environment. 
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Another disadvantage of aptamers for therapeutic applications is their short 
circulating half-life due to their small size. For therapeutic purposes, low molecular weight of 
aptamers is desirable as it results in economical chemical synthesis and better target 
accessibility. However, it causes rapid clearance by the renal system. Conjugation with high 
molecular weight polyethylene glycol was shown to prolong in vivo circulating half-life, 
thereby enhancing the pharmacokinetic profile (87, 88, 89). 
The next principal challenge in therapeutic application is delivery of the chemically 
modified aptamer. Our target antigens, Glia33Q and Glia33E, are available in the 
extracellular environment at the point of intended therapeutic intervention by the aptamers. 
Aptamer application is currently limited to parenteral administration such as injecting the 
drug directly at the site of action (e.g., intraocular injection). Systemic administration has 
proven to be feasible in animal models for several examples (90) and is now also being 
introduced to human application. Following the route of entry of the antigens, our intended 
mode of administration is oral. The complications associated with such an undertaking are 
obvious. The aptamers have to traverse the gastrointestinal tract which observes drastic 
changes in the pH environment (2.5-3.5 in stomach to 8.3-8.5 in the small intestine). To 
increase the bioavailability of the aptamers, PEGylation or conjugation with large moieties 
can be carried out. In addition to ensuring the stability of the aptamers, it is essential to 
ensure their rapid escape and protection from degradation. Liposomes have emerged as one 
of the most versatile tools for the delivery of DNA therapeutics (91, 92). At the neutral 
cellular pH 7, these lipids have a bilayer structure. However, upon endosomal 
compartmentalization they undergo protonation and collapse leading to the disruption and 
destabilization of the endosomal bilayer, which in turn helps in the rapid release of DNA into 
the cytoplasm (93). This could be a possible route for the aptamers against Glia33E on 
internalisation by the endosomes along with the antigenic peptide, before being loaded onto 
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the HLA-DQ molecules. Another approach is to use gastro- and intestine-resistant transport 
systems with pH-dependent coatings. These systems utilize polymeric carriers that are 
insoluble in the low pH media of the upper gastrointestinal tract, but dissolve at a higher, near 
neutral pH of the distal gut. The pH-dependent approach for colonic drug delivery is based on 
the pH differences along the gastrointestinal tract. It is critical that the drug is delivered near 
the Peyer’s patches (lamina propia) (94). A copolymer of methyl acrylate, methacrylic acid 
and methyl methacrylate ester marketed as Eudragit® FS, which is soluble at pH above 7.0, 
is a commonly used pH responsive polymer to facilitate drug delivery to the ileo-colonic 
region (95). 
We have reported ssDNA aptamers against the immunopotent 33mer gluten peptides 
that have been identified as triggers of Celiac Disease. Since their discovery almost 14 years 
ago, aptamers have emerged as a highly competitive class of molecules that rival antibodies 
in diagnostics and therapeutics. Unlike antibodies that are generated from animals and cell 
lines, aptamers are selected by an in vitro process. Aptamers also display little to no 
immunogenicity, which is important for human therapeutic applications.  
Our aptamers were tested in vitro, and were found to display significant promise by 
way of interfering with tTGase-mediated deamidation of Glia33Q and inhibiting the DQ2-
Glia33E interaction. This two point intervention strategy has not been used by any of the 
current therapeutic approaches to treat CD. Our aptamer-based therapeutic approach is an 
exciting project because it can be applied for the treatment of other autoimmune diseases 
where the antigen has been identified. An example is Multiple Sclerosis, a slowly 
progressive, autoimmune disease of the Central Nervous System, characterized by 
inflammation and demyelination of white matter in the brain and spinal cord. T-cell responses 
to Central Nervous System antigens, such as myelin basic protein, myelin oligodendrocyte 
glycoprotein and proteolipid protein, are considered a primary autoimmune event in Multiple 
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Sclerosis (96, 97). Another example could be Pemphigus Vulgaris, a blistering disease of the 
skin and mucous membranes. Autoantibodies specific for a keratinocyte cell adhesion 
molecule glycoprotein, desmoglein 3, cause a loss of cell adhesion and blister formation (98). 
For many autoimmune diseases, like Rheumatoid Arthritis, Type1 Diabetes among others, the 
primary antigens responsible for the inappropriate T-cell response are still to be identified. 
Once that missing piece is recognized, aptamer-based therapeutics can be developed specific 
to the disease. 
There is a general consensus that HLA-DQ-restricted CD4
+
 T-cells are pivotal in CD 
pathogenesis. However, the characterization of the complete repertoire of peptides involved 
in the pathogenesis of CD remains a daunting task because of the great heterogeneity of 
gluten proteins. So far, several T-cell stimulatory peptides from α-gliadin, γ-gliadin, and 
glutenins have been identified using mass spectrometry analysis or by screening large peptide 
libraries. However, it was demonstrated that a single 33-mer peptide of certain α-gliadin 
proteins displayed the optimal T-cell stimulatory capacity in CD patients (19). This 33-mer 
peptide, encompassing six copies of three reported T cell epitopes (DQ2-α-I, DQ2-α-II, and 
DQ2-α-III), is resistant to gastrointestinal proteolysis and binds efficiently to HLA-DQ2. 
Together, these properties add credence to the notion that this 33-mer peptide is the 
immunodominant T-cell stimulatory gluten peptide in HLA-DQ2
+
 CD patients (99, 100). Our 
work has been based on the aforementioned findings. However, it is unclear whether 
inhibiting the 33-mer peptides is enough to mitigate disease progression. It is probable that 
aptamers need to be raised against other HLA-DQ restricted epitopes. These would include 
the 25mer (101), 18mer (101), 17mer (102) and 13mer (103) from α-gliadin and peptides 
derived from γ-gliadin (101, 104, 105, 106). Administering a cocktail of the aptamers could 




Aptamers against Glia33Q and Glia33E are currently in the proof-of-concept stage. 
Devising a successful delivery system will ensure this technology has a substantial impact in 
CD patient care in the coming years. A projected dosage of Apt33E1.20 in neutralizing the 
Glia33E in 1 slice of bread is provided below. 
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Appendix A: HPLC and MALDI-MS profiles of Glia33Q and Glia33E peptides 
 
Figure A (i): RP-HPLC profile of Glia33Q 
 
 































Figure A (iii): MALDI profiles of Glia33Q. Theoretical MW of Glia33Q = 3911. Observed 
















































































Figure A (iv): MALDI profiles of Glia33E. Theoretical MW of Glia33E = 3914. Observed 




























































































































Figure B (i): Isotherms for titrating Glia33Q into buffer.  
 
 




APPENDIX C: T cell activation profiles using fixed and irradiated antigen presenting cells 
 
Figure C (i): T cell activation in presence of Apt33Q1.10, Apt33Q1.20 and control aptamer 
Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33Q) to aptamers were used. Fixed 
antigen presenting cells and T cell clone 678.3.22, specific for α-II were used. Decrease in 
count per minute indicates inhibition to T cell proliferation as a result of aptamer-Glia33Q 
interaction. 
 
Figure C (ii): T cell activation in presence of Apt33E1.10, Apt33E1.20, Apt33E1.30 and 
control aptamer Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33E) to aptamers 
were used. Fixed antigen presenting cells and T cell clone 430.1.142, specific for α-I/α-III 
were used. Decrease in cell count per minute indicates inhibition to T cell proliferation as a 
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Figure C (iii): T cell activation in presence of Apt33Q1.10, Apt33Q1.20 and control aptamer 
Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33Q) to aptamers were used. 
Irradiated antigen presenting cells and T cell clone 678.3.22, specific for α-II were used. 




Figure C (iv): T cell activation in presence of Apt33E1.10, Apt33E1.20, Apt33E1.30 and 
control aptamer Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33E) to aptamers 
were used. Irradiated antigen presenting cells and T cell clone 678.3.22, specific for α-II were 
used. Decrease in cell count per minute indicates inhibition to T cell proliferation as a result 
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Figure C (v): T cell activation in presence of Apt33Q1.10, Apt33Q1.20 and control aptamer 
Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33Q) to aptamers were used. 
Irradiated antigen presenting cells and T cell clone 430.1.142, specific for α-I/α-III were 
used. Decrease in cell count per minute indicates inhibition to T cell proliferation as a result 
of aptamer-Glia33Q interaction. 
 
 
Figure C (vi): T cell activation in presence of Apt33E1.10, Apt33E1.20, Apt33E1.30 and 
control aptamer Muc1S2.2. 1:1, 1:10 and 1:100 ratios of the antigen (Glia33E) to aptamers 
were used. Irradiated antigen presenting cells and T cell clone 430.1.142, specific for α-I/α-
III were used. Decrease in cell count per minute indicates inhibition to T cell proliferation as 
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